Evidence map›Paper›PMID 32154053›Full record

ArticleJIMD reports2020

Cystathionine beta synthase deficiency and brain edema associated with methionine excess under betaine supplementation: Four new cases and a review of the evidence.

Bernd C Schwahn, Thomas Scheffner, Hedwig Stepman, Peter Verloo, Anibh M Das, Janice Fletcher, Henk J Blom, Jean-Francois Benoist, Bruce A Barshop, Jaime J Barea and 1 more

Open access · goldAbstract readCase Reports
In one paragraph

Article in JIMD reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 16 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 7 countries.

Bernd C SchwahnWillink Metabolic Unit, Manchester Centre for Genomic Medicine Manchester University Hospitals NHS Foundation Trust Manchester UK.ORCID https://orcid.org/0000-0003-0961-2508
Thomas ScheffnerKlinikum am Steinenberg, Klinik für Kinder und Jugendmedizin School of Medicine University of Tübingen Reutlingen Germany.
Hedwig StepmanLaboratory for Metabolic diseases Ghent University Hospital Ghent Belgium.
Peter VerlooDepartment of Pediatric Neurology and Metabolic Diseases University Hospital Ghent Ghent Belgium.
Anibh M DasMedizinische Hochschule Hannover Klinik für Pädiatrische Nieren-, Leber- und Stoffwechselerkrankungen Hannover Germany.
Janice FletcherGenetics and Molecular Pathology SA Pathology Adelaide Australia.
Henk J BlomMetabolic Unit, Department of Clinical Genetics Center for Lysosomal and Metabolic Diseases. Erasmus Medical Center Rotterdam The Netherlands.
Jean-Francois BenoistService de Biochimie Hormonologie Hôpital Robert Debré, APHP Paris France.
Bruce A BarshopDepartment of Pediatrics, Division of Biochemical Genetics, Rady Children's Hospital-San Diego University of California San Diego California.
Jaime J BareaDepartment of Pediatrics, Division of Biochemical Genetics, Rady Children's Hospital-San Diego University of California San Diego California.
Annette FeigenbaumDepartment of Pediatrics, Division of Biochemical Genetics, Rady Children's Hospital-San Diego University of California San Diego California.
University of California San Diego · USGhent University Hospital · BEAssistance Publique – Hôpitaux de Paris · FRErasmus MC · NLKreiskliniken Reutlingen · DEMedizinische Hochschule Hannover · DESouth Australia Pathology · AUUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CBS deficient individuals undergoing betaine supplementation without sufficient dietary methionine restriction can develop severe hypermethioninemia and brain edema. Brain edema has also been observed in individuals with severe hypermethioninemia without concomitant betaine supplementation. We systematically evaluated reports from 11 published and 4 unpublished patients with CBS deficiency and from additional four cases of encephalopathy in association with elevated methionine. We conclude that, while betaine supplementation does greatly exacerbate methionine accumulation, the primary agent causing brain edema is methionine rather than betaine. Clinical signs of increased intracranial pressure have not been seen in patients with plasma methionine levels below 559 μmol/L but occurred in one patient whose levels did not knowingly exceed 972 μmol/L at the time of manifestation. While levels below 500 μmol/L can be deemed safe it appears that brain edema can develop with plasma methionine levels close to 1000 μmol/L. Patients with CBS deficiency on betaine supplementation need to be regularly monitored for concordance with their dietary plan and for plasma methionine concentrations. Recurrent methionine levels above 500 μmol/L should alert clinicians to check for clinical signs and symptoms of brain edema and review dietary methionine intake. Levels approaching 1000 μmol/L do increase the risk of complications and levels exceeding 1000 μmol/L, despite best dietetic efforts, should be acutely addressed by reducing the prescribed betaine dose.

Indexed as

adverse drug effectbetainebrain edemaCBS deficiencyencephalopathyhomocystinuria

Identifiers

PMID32154053
PMCPMC7052692
OpenAlexW3000493408

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.